CytoDyn Inc - Company & Market Research Reports

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man. The company is based in Vancouver, Washington.

From
From
From
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator
adroll